Illumina(ILMN) - 2026 Q4 - Annual Results

Revenue Performance - Revenue for Q4 2025 was approximately $1.155 billion, representing a 5% increase from Q4 2024 (4% on a constant currency basis) [7] - Ex-China revenue for Q4 2025 was approximately $1.100 billion, up 7% from Q4 2024 [7] - Full fiscal year 2025 revenue was approximately $4.34 billion, flat compared to 2024 [7] - Ex-China revenue for fiscal year 2025 was approximately $4.10 billion, up 2% from 2024 [7] - Constant currency revenue for Q4 2025, excluding hedge effects, was approximately $1.159 billion, a 5% increase from Q4 2024 [14] Earnings Per Share (EPS) - GAAP diluted EPS for Q4 2025 is projected to be between $2.14 and $2.17, while non-GAAP diluted EPS is expected to be between $1.27 and $1.30 [7] - GAAP diluted EPS for fiscal year 2025 is projected to be between $5.42 and $5.45, with non-GAAP diluted EPS expected between $4.76 and $4.79 [7] Business Acquisition and Integration - The company is in the process of acquiring SomaLogic, Inc., which may impact future financial results [9] - The company anticipates challenges in integrating the SomaLogic Business and managing partner relationships in the proteomics market [9] Forward-Looking Guidance - Forward-looking guidance is provided on a non-GAAP basis, with uncertainties regarding future financial measures due to various factors [8]